RxDoctor Payments Data

Anthony Musto, MD

Ophthalmology · Stratford, CTNPI 1205832938

Payments from drug & device makers

$486in general payments, 2019–2025

Across 30 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$265
  • Aerie Pharmaceuticals, Inc.$42
  • Alcon$36
  • Bausch & Lomb Americas Inc.$36
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$30
  • ANI Pharmaceuticals, Inc.$25
  • plus $52 from 3 others

What the payments were for

  • Food & beverage$486100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$486 in reported general payments places this provider in the 35th percentile of 279 ophthalmology providers in Connecticut.

See all ophthalmology providers in Connecticut

Medicare billing

Part B allowed, 2024
$30,787
Medicare patients
180
Services billed
371

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost107$72,754
RestasisCyclosporine22$24,653
VyzultaLatanoprostene Bunod22$17,103
Cyclosporine26$14,393
Travoprost70$10,209
Brinzolamide52$4,187
Latanoprost171$1,626
Ketorolac Tromethamine20$572
Dorzolamide Hcl30$386

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$15$97,407129 claims
Bausch & Lomb Americas Inc.Vyzulta$36$17,10322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 279 ophthalmology providers in Connecticut.

Other ophthalmology in Stratford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →